Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levoleucovorin/5-FU + Liposomal Irinotecan ± Cetuximab/Bevacizumab in 2L MSS mCRC
NCT07559760Phase 2Recruiting
- Sponsor
- The First Hospital of Jilin University
- Start
- Nov 2025
- Primary completion
- May 2027
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in colorectal cancer (CRC), sponsored by The First Hospital of Jilin University. Started Nov 2025; status: recruiting.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07559760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07559760.